vs

Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and Palladyne AI Corp. (PDYN). Click either name above to swap in a different company.

Palladyne AI Corp. is the larger business by last-quarter revenue ($1.7M vs $1.1M, roughly 1.5× Insight Molecular Diagnostics Inc.). Palladyne AI Corp. runs the higher net margin — -89.9% vs -2015.4%, a 1925.5% gap on every dollar of revenue. On growth, Palladyne AI Corp. posted the faster year-over-year revenue change (118.3% vs -23.4%). Insight Molecular Diagnostics Inc. produced more free cash flow last quarter ($-7.0M vs $-8.7M). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs -30.5%).

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Palladyne AI Corp. is an American company known for most of its existence primarily as a developer of robots. Palladyne was founded in 1983 as Sarcos Research Corporation. In 2023, Sarcos shifted its business focus to the development of artificial intelligence (AI) software for robotic applications, discontinuing its hardware operations. In March 2024, the company changed its name to Palladyne AI.

IMDX vs PDYN — Head-to-Head

Bigger by revenue
PDYN
PDYN
1.5× larger
PDYN
$1.7M
$1.1M
IMDX
Growing faster (revenue YoY)
PDYN
PDYN
+141.6% gap
PDYN
118.3%
-23.4%
IMDX
Higher net margin
PDYN
PDYN
1925.5% more per $
PDYN
-89.9%
-2015.4%
IMDX
More free cash flow
IMDX
IMDX
$1.7M more FCF
IMDX
$-7.0M
$-8.7M
PDYN
Faster 2-yr revenue CAGR
IMDX
IMDX
Annualised
IMDX
154.4%
-30.5%
PDYN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMDX
IMDX
PDYN
PDYN
Revenue
$1.1M
$1.7M
Net Profit
$-23.0M
$-1.5M
Gross Margin
42.5%
15.6%
Operating Margin
-2057.5%
-560.7%
Net Margin
-2015.4%
-89.9%
Revenue YoY
-23.4%
118.3%
Net Profit YoY
31.5%
97.2%
EPS (diluted)
$-0.75
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMDX
IMDX
PDYN
PDYN
Q4 25
$1.1M
$1.7M
Q3 25
$260.0K
$860.0K
Q2 25
$518.0K
$1.0M
Q1 25
$2.1M
$1.7M
Q4 24
$1.5M
$761.0K
Q3 24
$115.0K
$871.0K
Q2 24
$104.0K
$2.7M
Q1 24
$176.0K
$3.4M
Net Profit
IMDX
IMDX
PDYN
PDYN
Q4 25
$-23.0M
$-1.5M
Q3 25
$-10.9M
$-3.7M
Q2 25
$-9.7M
$-7.5M
Q1 25
$-6.7M
$22.8M
Q4 24
$-33.5M
Q3 24
$-13.5M
$-7.1M
Q2 24
$-4.5M
$-5.3M
Q1 24
$-9.1M
$-7.2M
Gross Margin
IMDX
IMDX
PDYN
PDYN
Q4 25
42.5%
15.6%
Q3 25
53.5%
46.4%
Q2 25
67.6%
53.3%
Q1 25
62.0%
79.4%
Q4 24
40.0%
27.2%
Q3 24
43.5%
45.0%
Q2 24
48.1%
79.0%
Q1 24
25.6%
45.2%
Operating Margin
IMDX
IMDX
PDYN
PDYN
Q4 25
-2057.5%
-560.7%
Q3 25
-4249.2%
-937.8%
Q2 25
-1900.0%
-797.4%
Q1 25
-318.0%
-405.3%
Q4 24
-2262.9%
Q3 24
-11752.2%
-838.0%
Q2 24
-4453.8%
-213.3%
Q1 24
-5265.3%
-213.7%
Net Margin
IMDX
IMDX
PDYN
PDYN
Q4 25
-2015.4%
-89.9%
Q3 25
-4174.6%
-434.9%
Q2 25
-1880.7%
-737.6%
Q1 25
-312.0%
1330.9%
Q4 24
-2255.1%
Q3 24
-11733.0%
-814.7%
Q2 24
-4355.8%
-196.2%
Q1 24
-5186.9%
-210.1%
EPS (diluted)
IMDX
IMDX
PDYN
PDYN
Q4 25
$-0.75
$-0.02
Q3 25
$-0.34
$-0.09
Q2 25
$-0.30
$-0.20
Q1 25
$-0.26
$0.55
Q4 24
$-2.19
Q3 24
$-0.98
$-0.27
Q2 24
$-0.36
$-0.20
Q1 24
$-1.13
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMDX
IMDX
PDYN
PDYN
Cash + ST InvestmentsLiquidity on hand
$11.6M
$47.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$-31.5M
$74.7M
Total Assets
$25.8M
$95.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMDX
IMDX
PDYN
PDYN
Q4 25
$11.6M
$47.1M
Q3 25
$18.7M
$57.1M
Q2 25
$24.3M
$62.7M
Q1 25
$31.0M
$46.6M
Q4 24
$8.6M
$40.1M
Q3 24
$3.4M
$21.3M
Q2 24
$9.3M
$25.8M
Q1 24
$5.6M
$31.8M
Stockholders' Equity
IMDX
IMDX
PDYN
PDYN
Q4 25
$-31.5M
$74.7M
Q3 25
$-9.2M
$51.8M
Q2 25
$1.1M
$53.8M
Q1 25
$10.2M
$28.3M
Q4 24
$-12.3M
$-9.5M
Q3 24
$9.7M
$23.4M
Q2 24
$22.7M
$29.8M
Q1 24
$11.6M
$34.2M
Total Assets
IMDX
IMDX
PDYN
PDYN
Q4 25
$25.8M
$95.7M
Q3 25
$43.9M
$72.9M
Q2 25
$50.5M
$78.3M
Q1 25
$60.4M
$63.3M
Q4 24
$35.1M
$56.3M
Q3 24
$70.2M
$38.7M
Q2 24
$74.7M
$45.1M
Q1 24
$71.0M
$50.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMDX
IMDX
PDYN
PDYN
Operating Cash FlowLast quarter
$-5.5M
$-8.5M
Free Cash FlowOCF − Capex
$-7.0M
$-8.7M
FCF MarginFCF / Revenue
-616.7%
-526.2%
Capex IntensityCapex / Revenue
129.9%
14.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMDX
IMDX
PDYN
PDYN
Q4 25
$-5.5M
$-8.5M
Q3 25
$-4.5M
$-6.3M
Q2 25
$-6.3M
$-5.3M
Q1 25
$-5.9M
$-7.5M
Q4 24
$-5.4M
$-22.6M
Q3 24
$-5.5M
$-4.5M
Q2 24
$-6.0M
$-5.8M
Q1 24
$-3.8M
$-7.2M
Free Cash Flow
IMDX
IMDX
PDYN
PDYN
Q4 25
$-7.0M
$-8.7M
Q3 25
$-5.6M
$-6.7M
Q2 25
$-6.6M
Q1 25
$-6.2M
$-7.6M
Q4 24
$-5.6M
$-22.9M
Q3 24
$-5.6M
$-4.5M
Q2 24
$-6.2M
$-5.9M
Q1 24
$-3.9M
$-7.3M
FCF Margin
IMDX
IMDX
PDYN
PDYN
Q4 25
-616.7%
-526.2%
Q3 25
-2135.4%
-776.0%
Q2 25
-1279.5%
Q1 25
-288.4%
-445.0%
Q4 24
-374.5%
-3008.1%
Q3 24
-4884.3%
-517.8%
Q2 24
-5931.7%
-218.9%
Q1 24
-2189.8%
-212.1%
Capex Intensity
IMDX
IMDX
PDYN
PDYN
Q4 25
129.9%
14.2%
Q3 25
403.8%
44.7%
Q2 25
67.4%
0.0%
Q1 25
14.4%
5.4%
Q4 24
14.4%
34.8%
Q3 24
75.7%
1.4%
Q2 24
183.7%
5.3%
Q1 24
13.6%
1.8%
Cash Conversion
IMDX
IMDX
PDYN
PDYN
Q4 25
Q3 25
Q2 25
Q1 25
-0.33×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons